Company Performance - Hims & Hers Health stock has surged 165.9% in the past year, with earnings estimates for 2024 increasing from 18 cents to 19 cents and for 2025 from 33 cents to 35 cents in the past week [1] - HIMS has beaten earnings estimates in three of the last four quarters, with an average surprise of 79.2% and a staggering 150% surprise in the last reported quarter [4] - ResMed's fiscal 2024 earnings per share estimates have remained constant at $7.70, with shares declining 1.6% over the past year compared to the industry's fall of 1.7% [5] - Medpace's 2024 earnings per share estimates have remained constant at $11.29, with shares surging 81.9% in the past year compared to the industry's 5% growth [14] - ResMed has surpassed earnings estimates in three of the last four quarters, with an average surprise of 2.8% [15] Quest Diagnostics Overview - Quest Diagnostics is experiencing robust volume growth driven by increased demand for its services, with base business revenues increasing nearly 6% in the first quarter of 2024 [6] - The company has made significant strides in its Professional Lab Services relationships, contributing to its growth [2] - Quest Diagnostics has a strong customer base, with approximately 90% of health plan members in the U.S. having access to its laboratory services [7] - The company is benefiting from a broad health plan access and strong ties with health plans, resulting in significant revenue increases compared to the previous year [6] Competitive Landscape - Quest Diagnostics faces intense competition from LabCorp, other commercial laboratories, and hospitals, with service quality being a key competitive factor [8] - The company is poised to deliver accessible and affordable laboratory testing, helping health systems improve productivity and patient care [2] - Despite strong growth, Quest Diagnostics is challenged by declining testing revenues, particularly due to a rapid transition away from COVID-19 testing, which saw a nearly 85% revenue drop in 2023 [12][11] M&A and Growth Opportunities - Quest Diagnostics has a promising M&A pipeline, with recent acquisitions contributing to its growth [2] - The company is well-positioned to capitalize on sustained high healthcare utilization rates and continue driving new customer growth [6]

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call. About Quest Diagnostics Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion o ...

Company Overview - Quest Diagnostics has completed the acquisition of PathAI Diagnostics, enhancing its leadership in oncology and subspecialized pathology services [6] - The acquisition aims to accelerate the adoption of AI and digital pathology to improve cancer diagnosis and other diseases [6][20] - The PathAI Diagnostics facility in Memphis has been rebranded as AmeriPath, serving as a national AI and digital R&D center for Quest Diagnostics [13] Industry Insights - The global AI in pathology market was valued at $24 million in 2023 and is projected to grow at a CAGR of 15.6% by 2030 [21] - AI in pathology offers advantages such as improved accuracy, increased efficiency, and enhanced patient care, driven by the demand for better diagnosis and cost control in hospitals [2] - Digital pathology enables the creation of digital images of glass slides, facilitating expert consultations and reducing transportation needs, which addresses workforce shortages in pathology [8] Strategic Collaborations - Quest Diagnostics will license PathAI's AISight digital pathology image management system to enhance its pathology laboratories and customer sites in the U.S. [7] - Both companies may collaborate on developing AI algorithms for research and clinical applications [14] - A research collaboration with Broad Clinical Labs has been announced to demonstrate the clinical value of whole genome sequencing as a first-line genetic test for developmental delay disorders [22] Financial Performance - Quest Diagnostics currently holds a Zacks Rank 3 (Hold) [10] - In the past year, shares of Quest Diagnostics have decreased by 1.2%, while the industry has risen by 15.2% [23]

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/ -- A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in J ...

Quest Diagnostics Q1 Earnings Surpass, Margins Crash Quest Diagnostics Incorporated's first-quarter 2024 adjusted earnings per share of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure. Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter's adjusted figures. GAAP ...

SECAUCUS, N.J., May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members. Rob CarterRob Carter Mr. Carter, 64, is Executive Vice President and Chief Information Officer at FedEx Corporation, where he is responsible for setting the technology direction of the F ...

SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024. SOURCE Quest Diagnostics About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from ...

Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escalated in States That Have Legalized Recreational Marijuana as well as in Professional Office-Based Industries SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior y ...

SECAUCUS, N.J., May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time. The fireside chat and Q&A session will be webcast live during the conf ...

Quest Diagnostics (DGX) recently announced a strategic collaboration with PathAI, a global leader in artificial intelligence-powered pathology technology, aimed at revolutionizing cancer and disease diagnosis. This partnership marks a significant step toward accelerated adoption of AI and digital pathology in Quest Diagnostics’ diagnostic services, promising enhanced quality, speed and efficiency in healthcare.Transformative Acquisition of PathAI Diagnostics AssetsUnder this definitive agreement, Quest Diag ...